RESUMEN
The US population reflects a rich diversity of people that is not reflected in the health care workforce. This article describes the Adelante (Moving Forward) Program, an innovative model designed to increase nursing workforce diversity. Adelante was created to advance baccalaureate nursing students and prenursing students by using supportive developmental relationships and mentoring strategies. Graduates stated that they planned to advance their education. Further development of innovative programs for nursing students from diverse backgrounds is imperative to increase health care workforce diversity.
Asunto(s)
Bachillerato en Enfermería/organización & administración , Relaciones Interprofesionales , Tutoría , Estudiantes de Enfermería/psicología , Diversidad Cultural , Difusión de Innovaciones , Humanos , Investigación en Educación de Enfermería , Investigación en Evaluación de Enfermería , Personal de Enfermería/estadística & datos numéricosRESUMEN
Complement C1q is part of the C1 macromolecular complex that mediates the classical complement activation pathway: a major arm of innate immune defense. C1q is composed of A, B, and C chains that require post-translational prolyl 4-hydroxylation of their N-terminal collagen-like domain to enable the formation of the functional triple helical multimers. The prolyl 4-hydroxylase(s) that hydroxylate C1q have not previously been identified. Recognized prolyl 4-hydroxylases include collagen prolyl-4-hydroxylases (CP4H) and the more recently described prolyl hydroxylase domain (PHD) enzymes that act as oxygen sensors regulating hypoxia-inducible factor (HIF). We show that several small-molecule prolyl hydroxylase inhibitors that activate HIF also potently suppress C1q secretion by human macrophages. However, reducing oxygenation to a level that activates HIF does not compromise C1q hydroxylation. In vitro studies showed that a C1q A chain peptide is not a substrate for PHD2 but is a substrate for CP4H1. Circulating levels of C1q did not differ between wild-type mice or mice with genetic deficits in PHD enzymes, but were reduced by prolyl hydroxylase inhibitors. Thus, C1q is hydroxylated by CP4H, but not the structurally related PHD hydroxylases. Hence, reduction of C1q levels may be an important off-target side effect of small molecule PHD inhibitors developed as treatments for renal anemia.
Asunto(s)
Complemento C1q/metabolismo , Prolina Dioxigenasas del Factor Inducible por Hipoxia/metabolismo , Hipoxia/metabolismo , Macrófagos/metabolismo , Procolágeno-Prolina Dioxigenasa/metabolismo , Inhibidores de Prolil-Hidroxilasa/farmacología , Anemia/tratamiento farmacológico , Anemia/etiología , Animales , Línea Celular , Complemento C1q/análisis , Vía Clásica del Complemento , Femenino , Humanos , Hidroxilación , Enfermedades Renales/sangre , Enfermedades Renales/tratamiento farmacológico , Enfermedades Renales/patología , Macrófagos/efectos de los fármacos , Masculino , Ratones , Ratones Endogámicos C57BL , Procolágeno-Prolina Dioxigenasa/antagonistas & inhibidores , Inhibidores de Prolil-Hidroxilasa/uso terapéutico , Procesamiento Proteico-PostraduccionalRESUMEN
BACKGROUND: The Affordable Care Act of 2010 emphasized the importance of primary care and preventative services as core components to promote the health of the U.S. METHOD: A unique program was created for baccalaureate nursing students to provide learning and practice experiences in primary practice sites that emphasized chronic disease prevention and management, including mental health and substance abuse services. Students were selected using a holistic approach. RESULTS: Students were selected to participate in the project. A community leadership advisory board was created. Students were assigned to the Veteran Administration's primary care clinics for their clinical experiences. CONCLUSION: This project is well-developed to increase the knowledge of present and future RNs, interprofessional providers and educators, researchers, and policy makers in community-oriented primary care. [J Nurs Educ. 2021;60(3):129-135.].
Asunto(s)
Bachillerato en Enfermería , Atención Primaria de Salud , Bachillerato en Enfermería/métodos , Humanos , Aprendizaje , Patient Protection and Affordable Care Act , Estudiantes de Enfermería , Enseñanza , Estados UnidosRESUMEN
Indoleamine 2,3-dioxygenase 1 (IDO1), a heme-containing enzyme that mediates the rate-limiting step in the metabolism of l-tryptophan to kynurenine, has been widely explored as a potential immunotherapeutic target in oncology. We developed a class of inhibitors with a conformationally constrained bicyclo[3.1.0]hexane core. These potently inhibited IDO1 in a cellular context by binding to the apoenzyme, as elucidated by biochemical characterization and X-ray crystallography. A SKOV3 tumor model was instrumental in differentiating compounds, leading to the identification of IACS-9779 (62) and IACS-70465 (71). IACS-70465 has excellent cellular potency, a robust pharmacodynamic response, and in a human whole blood assay was more potent than linrodostat (BMS-986205). IACS-9779 with a predicted human efficacious once daily dose below 1 mg/kg to sustain >90% inhibition of IDO1 displayed an acceptable safety margin in rodent toxicology and dog cardiovascular studies to support advancement into preclinical safety evaluation for human development.
Asunto(s)
Descubrimiento de Drogas , Inhibidores Enzimáticos/farmacología , Indolamina-Pirrol 2,3,-Dioxigenasa/antagonistas & inhibidores , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/síntesis química , Inhibidores Enzimáticos/química , Humanos , Indolamina-Pirrol 2,3,-Dioxigenasa/metabolismo , Estructura Molecular , Relación Estructura-ActividadRESUMEN
Inhibition of glutaminase-1 (GLS-1) hampers the proliferation of tumor cells reliant on glutamine. Known glutaminase inhibitors have potential limitations, and in vivo exposures are potentially limited due to poor physicochemical properties. We initiated a GLS-1 inhibitor discovery program focused on optimizing physicochemical and pharmacokinetic properties, and have developed a new selective inhibitor, compound 27 (IPN60090), which is currently in phase 1 clinical trials. Compound 27 attains high oral exposures in preclinical species, with strong in vivo target engagement, and should robustly inhibit glutaminase in humans.
Asunto(s)
Inhibidores Enzimáticos/química , Glutaminasa/antagonistas & inhibidores , Triazoles/farmacocinética , Administración Oral , Animales , Línea Celular Tumoral , Perros , Evaluación Preclínica de Medicamentos , Inhibidores Enzimáticos/metabolismo , Inhibidores Enzimáticos/farmacocinética , Glutaminasa/genética , Glutaminasa/metabolismo , Semivida , Hepatocitos/citología , Hepatocitos/efectos de los fármacos , Hepatocitos/metabolismo , Humanos , Concentración 50 Inhibidora , Masculino , Ratones , Microsomas/metabolismo , Unión Proteica , Ratas , Ratas Sprague-Dawley , Proteínas Recombinantes/biosíntesis , Proteínas Recombinantes/química , Proteínas Recombinantes/aislamiento & purificación , Relación Estructura-Actividad , Triazoles/química , Triazoles/metabolismoRESUMEN
Since the implementation of the Papanicolaou test, there has been a significant decline in the incidence of cervical cancer over the last 50 years. Despite this reduction, each year there are approximately 11,000 women in the United States diagnosed with cervical cancer, the second most common type of cancer in women worldwide. Infection with oncogenic human papillomavirus (HPV) is necessary for the development of precancerous lesions and the progression to cervical cancer. For those diagnosed with an HPV infection or cervical cancer, a considerable personal and financial burden often results. Recent analyses estimate that the total direct costs associated with cervical dysplasia and cancer are extensive. Additionally, a patient's quality of life (social, emotional, and sexual functioning) is adversely affected following a diagnosis with an HPV infection or cervical cancer. The data also show disparities in the incidence of cervical cancer and barriers that may contribute to these phenomena in underserved populations. National programs have been implemented and can help reduce the burden of disease, but vaccination against HPV remains the primary method of prevention. In the healthcare field, nurses play many roles, a prominent one being a patient educator. As a result, there is a need to educate nurses about the risks and impact of HPV and cervical cancer. Nurses can be instrumental in educating the public about vaccination and increasing awareness of HPV and cervical cancer among the underserved.
Asunto(s)
Adenocarcinoma/patología , Carcinoma de Células Escamosas/patología , Área sin Atención Médica , Grupos Minoritarios , Rol de la Enfermera , Neoplasias del Cuello Uterino/prevención & control , Adulto , Vacunas contra el Cáncer , Costo de Enfermedad , Femenino , Humanos , Papillomaviridae , Estados Unidos/epidemiología , Neoplasias del Cuello Uterino/epidemiología , Neoplasias del Cuello Uterino/mortalidad , Neoplasias del Cuello Uterino/patologíaRESUMEN
The plasticity of a preexisting regulatory circuit compromises the effectiveness of targeted therapies, and leveraging genetic vulnerabilities in cancer cells may overcome such adaptations. Hereditary leiomyomatosis renal cell carcinoma (HLRCC) is characterized by oxidative phosphorylation (OXPHOS) deficiency caused by fumarate hydratase (FH) nullizyogosity. To identify metabolic genes that are synthetically lethal with OXPHOS deficiency, we conducted a genetic loss-of-function screen and found that phosphogluconate dehydrogenase (PGD) inhibition robustly blocks the proliferation of FH mutant cancer cells both in vitro and in vivo. Mechanistically, PGD inhibition blocks glycolysis, suppresses reductive carboxylation of glutamine, and increases the NADP+/NADPH ratio to disrupt redox homeostasis. Furthermore, in the OXPHOS-proficient context, blocking OXPHOS using the small-molecule inhibitor IACS-010759 enhances sensitivity to PGD inhibition in vitro and in vivo. Together, our study reveals a dependency on PGD in OXPHOS-deficient tumors that might inform therapeutic intervention in specific patient populations.
Asunto(s)
Fosforilación Oxidativa , Fosfogluconato Deshidrogenasa/genética , Mutaciones Letales Sintéticas , Animales , Línea Celular Tumoral , Femenino , Fumarato Hidratasa/genética , Genómica/métodos , Glucólisis , Humanos , Mutación con Pérdida de Función , Ratones , Ratones DesnudosRESUMEN
We report the structure-based design and synthesis of a novel series of aza-benzimidazoles as PHD2 inhibitors. These efforts resulted in compound 22, which displayed highly potent inhibition of PHD2 function in vitro.
Asunto(s)
Compuestos Aza/síntesis química , Compuestos Aza/farmacología , Bencimidazoles/síntesis química , Bencimidazoles/farmacología , Subunidad alfa del Factor 1 Inducible por Hipoxia/antagonistas & inhibidores , Procolágeno-Prolina Dioxigenasa/antagonistas & inhibidores , Compuestos Aza/química , Factores de Transcripción con Motivo Hélice-Asa-Hélice Básico , Bencimidazoles/química , Técnicas Químicas Combinatorias , Cristalografía por Rayos X , Humanos , Prolina Dioxigenasas del Factor Inducible por Hipoxia , Modelos Moleculares , Estructura Molecular , Relación Estructura-ActividadRESUMEN
Inhibition of the PHD2 enzyme has been associated with increased red blood cell levels. From a screening hit, a series of novel hydroxyl-thiazoles were developed as potent PHD2 inhibitors.
Asunto(s)
Subunidad alfa del Factor 1 Inducible por Hipoxia/síntesis química , Tiazoles/química , Química Farmacéutica/métodos , Diabetes Mellitus/tratamiento farmacológico , Diseño de Fármacos , Evaluación Preclínica de Medicamentos/métodos , Eritrocitos/enzimología , Humanos , Subunidad alfa del Factor 1 Inducible por Hipoxia/química , Concentración 50 Inhibidora , Modelos Químicos , Modelos Moleculares , Infarto del Miocardio/tratamiento farmacológico , Enfermedades Vasculares Periféricas/terapia , Accidente Cerebrovascular/tratamiento farmacológico , Relación Estructura-Actividad , Tiazoles/farmacologíaRESUMEN
Delivery of protein therapeutics often requires frequent injections because of low activity or rapid clearance, thereby placing a burden on patients and caregivers. Using glycoengineering, we have increased and prolonged the activity of proteins, thus allowing reduced frequency of administration. Glycosylation analogs with new N-linked glycosylation consensus sequences introduced into the protein were screened for the presence of additional N-linked carbohydrates and retention of in vitro activity. Suitable consensus sequences were combined in one molecule, resulting in glycosylation analogs of rHuEPO, leptin, and Mpl ligand. All three molecules had substantially increased in vivo activity and prolonged duration of action. Because these proteins were of three different classes (rHuEPO is an N-linked glycoprotein, Mpl ligand an O-linked glycoprotein, and leptin contains no carbohydrate), glycoengineering may be generally applicable as a strategy for increasing the in vivo activity and duration of action of proteins. This strategy has been validated clinically for glycoengineered rHuEPO (darbopoetin alfa).
Asunto(s)
Sistemas de Liberación de Medicamentos/métodos , Glicoproteínas/biosíntesis , Glicoproteínas/genética , Ingeniería de Proteínas/métodos , Proteínas/uso terapéutico , Anemia/tratamiento farmacológico , Animales , Células CHO/metabolismo , Células COS/metabolismo , Cricetinae , Eritropoyetina/genética , Eritropoyetina/metabolismo , Eritropoyetina/uso terapéutico , Excipientes/química , Femenino , Mejoramiento Genético/métodos , Glicoproteínas/metabolismo , Humanos , Leptina/biosíntesis , Leptina/deficiencia , Leptina/genética , Leptina/uso terapéutico , Ratones , Ratones Endogámicos BALB C , Proteínas/administración & dosificación , Proteínas Recombinantes/biosíntesis , Proteínas Recombinantes/genética , Proteínas Recombinantes/uso terapéutico , Trombopoyetina/biosíntesis , Trombopoyetina/uso terapéuticoRESUMEN
OBJECTIVE: Darbepoetin alfa, a novel erythropoiesis-stimulating protein, is a glycosylation analog of recombinant human erythropoietin (rHuEPO) with two additional N-linked carbohydrates. Used to treat anemia of cancer, chemotherapy, and kidney disease, it has a three-fold longer serum half-life and increased in vivo activity, but decreased receptor-binding activity. Glycosylation analogs with altered N-linked carbohydrate content were compared with rHuEPO to elucidate the relationship between carbohydrate content and activity. METHODS: EPO glycosylation analogs and rHuEPO were expressed and, in some cases, purified from Chinese hamster ovary cells and carbohydrate characterized by Western blotting. Assays were performed to compare in vitro receptor binding and in vivo activity of rHuEPO, darbepoetin alfa, and analogs. RESULTS: Reduced receptor binding of darbepoetin alfa could be accounted for entirely by increased sialic acid content and not by carbohydrate-related stearic hindrance or by amino acid differences. Shapes of dose-response curves, maximal responses in proliferation and colony assays, and magnitude and duration of downstream signaling events were comparable in vitro for rHuEPO and darbepoetin alfa. The in vivo response correlated with the number of N-linked carbohydrates. The number of carbohydrates was a more significant determinant for in vivo activity than position. The differences in in vivo erythropoietic activity among glycosylation analogs were more evident with increased time following administration in exhypoxic polycythemic mice. CONCLUSION: Carbohydrate increases persistence of EPO, resulting in a prolonged and increased biological response in vivo, and overcoming reduced receptor-binding activity.